



CDER Small Business and Industry Assistance Webinars 2024



M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms - *Implementing the Final Guidance*

November 21, 2024, 1:00 – 3:00 pm EDT

1:00 – 1:05 pm

Welcome and Overview

Kori Adair, PharmD

Pharmacist | Small Business and Industry Assistance (SBIA)
Division of Drug Information (DDI) | Office of Communications (OCOMM)
Center for Drug Evaluation and Research (CDER)

1:05 – 2:00 pm

Presentations

Lei Zhang, PhD

Deputy Director | Office of Research and Standards (ORS)
Office of Generic Drugs (OGD)

Nilufer Tampal, PhD

Associate Director of Scientific Quality | Office of Bioequivalence (OB) | OGD

Myong-Jin (MJ) Kim, PharmD

Director | Division of Therapeutic Performance II (DTPII) | ORS | OGD

2:00 – 2:30 pm

Discussion Panel

Moderator:

Sarah A. Ibrahim, PhD

Associate Director for Stakeholder and Global Engagement | OGD

Speakers and Additional Panelists:

Robert Lionberger, PhD

Director | ORS | OGD

Partha Roy, PhD

Director | OB | OGD

Dave Coppersmith, JD

Regulatory Counsel | Division of Policy Development (DPD) | Office of Generic Drug Policy (OGDP) | OGD

Qi Zhang, PhD

Immediate Release Drug Products Team Leader | DTPII | ORS | OGD

2:30 – 2:55 pm

Question and Answer Session

Moderator:

Kori Adair, PharmD

All presenters and panelists participate

2:55 – 3:00 pm

Closing Remarks

Robert Lionberger, PhD

Director | ORS | OGD